Research & Development
Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours
22 May 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Friday that Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monoth...
Allergan Aesthetics reports positive CHMP opinion recommending approval of Boey (trenibotulinumtoxinE)
22 May 2026 - Allergan Aesthetics, an AbbVie company (NYSE:ABBV) focused on medical aesthetics, announced on Thursday that the European Medicines Agency's (EMA) Committee for Medicinal Products f...
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
21 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted Priority Rev...
Upsher-Smith launches generic Cyclosporine Ophthalmic Emulsion 0.05%
21 May 2026 - Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co Ltd (TW:6472 and OTCQX:BORAY), announced on Wednesday that it has launched its Cyclosporine Ophthalmic Emulsion 0.0...
BioMarin Pharmaceutical meets primary endpoint in Phase 3 study of VOXZOGO in children with hypochondroplasia
21 May 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Wednesday that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO (vosoritide) in ...
Medtronic plans to SPR Therapeutics for USD650m to expand pain management portfolio
20 May 2026 - Healthcare technology company Medtronic plc (NYSE: MDT) announced on Wednesday that it intends to acquire privately held SPR Therapeutics Inc for approximately USD650m in cash, expanding...